Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/30133
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReste, M-
dc.contributor.authorAjazi, K-
dc.contributor.authorSayi-Yazgan, A-
dc.contributor.authorJankovic, R-
dc.contributor.authorBufan, B-
dc.contributor.authorBrandau, S-
dc.contributor.authorBækkevold, ES-
dc.contributor.authorPetitprez, F-
dc.contributor.authorLindstedt, M-
dc.contributor.authorAdema, GJ-
dc.contributor.authorAlmeida, CR-
dc.date.accessioned2024-11-15T11:38:19Z-
dc.date.available2024-11-15T11:38:19Z-
dc.date.issued2024-10-11-
dc.identifierORCiD: Ayça Sayi Yazgan https://orcid.org/0000-0002-9015-8244-
dc.identifier1439413-
dc.identifier.citationReste, M. et al. (2024) 'The role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseases', Frontiers in Immunology, 15, 1439413, pp. 1 - 13. doi: 10.3389/fimmu.2024.1439413.en_US
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/30133-
dc.descriptionIn the published article, there was an error in the Funding statement. The section originally stated that “COST is supported by the EU Framework Program Horizon 2020”, while it should refer to “Horizon Europe”. The correct Funding statement appears below. “The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was developed within the scope of projects with references UIDB/04501/2020 and https://doi.org/10.54499/UIDB/04501/2020, UIDP/04501/2020 and https://doi.org/10.54499/UIDP/04501/2020, 2022.03217.PTDC and DOI 10.54499/2022.03217.PTDC, financially supported by national funds (OE), through FCT - Fundação para a Ciência e Tecnologia, I.P./MCTES. This work was also supported by the World Scleroderma Foundation and Edit Busch Stiftung (MAPFib). This work has been supported by Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade, Faculty of Medicine No: 451-03-66/2024-03/200110. This work was funded by the Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161. This work was supported by the Wellcome Trust (225021/Z/22/Z). This work was supported by the Swedish Cancer Society (22 2221.Pj.01.H) and Mrs. Berta Kamprad’s Cancer Foundation (FBKS-2022-8-368). This work was supported by the Scientific and Technological Research Council of Turkey- TUBITAK (119S447 and 22AG077). This work was also supported by European Cooperation in Science and Technology (COST) Action CA20117 Mye-InfoBank (www.mye-infobank.eu); COST is supported by the EU Framework Program Horizon Europe.” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.-
dc.description.abstractTertiary Lymphoid Structures (TLS) are organized aggregates of immune cells such as T cells, B cells, and Dendritic Cells (DCs), as well as fibroblasts, formed postnatally in response to signals from cytokines and chemokines. Central to the function of TLS are DCs, professional antigen-presenting cells (APCs) that coordinate the adaptive immune response, and which can be classified into different subsets, with specific functions, and markers. In this article, we review current data on the contribution of different DC subsets to TLS function in cancer and autoimmunity, two opposite sides of the immune response. Different DC subsets can be found in different tumor types, correlating with cancer prognosis. Moreover, DCs are also present in TLS found in autoimmune and inflammatory conditions, contributing to disease development. Broadly, the presence of DCs in TLS appears to be associated with favorable clinical outcomes in cancer while in autoimmune pathologies these cells are associated with unfavorable prognosis. Therefore, it is important to analyze the complex functions of DCs within TLS in order to enhance our fundamental understanding of immune regulation but also as a possible route to create innovative clinical interventions designed for the specific needs of patients with diverse pathological diseases.en_US
dc.description.sponsorshipThis work was developed within the scope of projects with references UIDB/04501/2020 and https://doi.org/10.54499/UIDB/04501/2020, UIDP/04501/2020 and https://doi.org/10.54499/UIDP/04501/2020, 2022.03217.PTDC and DOI 10.54499/2022.03217.PTDC, financially supported by national funds (OE), through FCT - Fundação para a Ciência e Tecnologia, I.P./MCTES. This work was also supported by the World Scleroderma Foundation and Edit Busch Stiftung (MAPFib). This work has been supported by Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade, Faculty of Medicine No: 451-03-66/2024-03/200110. This work was funded by the Ministry of Science, Technological Development and Innovation, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-47/2023-01/200161. This work was supported by the Wellcome Trust (225021/Z/22/Z). This work was supported by the Swedish Cancer Society (22 2221.Pj.01.H) and Mrs. Berta Kamprad’s Cancer Foundation (FBKS-2022-8-368). This work was supported by the Scientific and Technological Research Council of Turkey- TUBITAK (119S447 and 22AG077). This work was also supported by European Cooperation in Science and Technology (COST) Action CA20117 Mye-InfoBank (www.mye-infobank.eu); COST is supported by the EU Framework Program Horizon Europe.en_US
dc.format.extent1 - 13-
dc.format.mediumElectronic-
dc.languageEnglish-
dc.language.isoen_USen_US
dc.publisherFrontiers Mediaen_US
dc.rightsAttribution 4.0 International-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjecttertiary lymphoid structures (TLS)en_US
dc.subjecttertiary lymphoid organs (TLO)en_US
dc.subjectdendritic cells (DC)en_US
dc.subjectanti-tumor immunityen_US
dc.subjectautoimmunityen_US
dc.titleThe role of dendritic cells in tertiary lymphoid structures: implications in cancer and autoimmune diseasesen_US
dc.typeArticleen_US
dc.date.dateAccepted2024-09-23-
dc.identifier.doihttps://doi.org/10.3389/fimmu.2024.1439413-
dc.relation.isPartOfFrontiers in Immunology-
pubs.publication-statusPublished online-
pubs.volume15-
dc.identifier.eissn1664-3224-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/legalcode.en-
dc.rights.holderReste, Ajazi, Sayi-Yazgan, Jankovic, Bufan, Brandau, Bækkevold, Petitprez, Lindstedt, Adema and Almeida-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2024 Reste, Ajazi, Sayi-Yazgan, Jankovic, Bufan, Brandau, Bækkevold, Petitprez, Lindstedt, Adema and Almeida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.1.24 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons